We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The long-running game of escalating bids for control of Croatian generic drugmaker Pliva appears to be over as Actavis has folded its hand and left Barr Pharmaceuticals as the only player at the table.